Comparison of the Efficacy and Tolerability of Gefitinib with Pemetrexed Maintenance After First-line Platinum-based Doublet Chemotherapy in Advanced Lung Adenocarcinoma: Single-center Experience

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2016 Oct 30

PMID 27789961

Citations 5

Authors

Liping Lin

Juanjuan Zhao

Jiazhu Hu

Fuxi Huang

Jianjun Han

Yan He

Xiaolong Cao

Affiliations

Soon will be listed here.

Abstract

Purpose: Both gefitinib and pemetrexed maintenance were effective therapies for advanced lung adenocarcinoma, but which is better is unclear. For patients with advanced lung adenocarcinoma, we have no idea whether we should choose gefitinib or pemetrexed maintenance in clinical practice. Here, we assessed the efficacy and tolerability of gefitinib versus pemetrexed maintenance in these patients.

Patients And Methods: A total of 101 patients were identified and divided into gefitinib (n=53) or pemetrexed (n=48) maintenance. Epidermal growth factor receptor (EGFR) status of tumors was analyzed in 67 patients. Disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were compared between the two groups.

Results: The results showed that DCR (79.2% vs 75%, =0.642) was similar between gefitinib and pemetrexed groups. The PFS of gefitinib was significantly longer than that of pemetrexed (8 months vs 5.4 months, hazard ratio [HR]: 0.520, 95% confidence interval [CI]: 0.341-0.791, =0.002); however, the OS was similar (19.9 months vs 18.8 months, HR: 1.006, 95% CI: 0.664-1.525, =0.977). In EGFR mutation-positive patients, PFS was significantly longer in gefitinib (12 months vs 5.4 months; HR: 0.158, 95% CI: 0.074-0.333, <0.001), whereas in EGFR wild-type subgroup gefitinib had a significantly shorter PFS than that by pemetrexed (2.5 months vs 5 months; HR: 2.822, 95% CI: 1.137-7.005, =0.025). Cox multivariate regression analysis of PFS for overall population showed that smoking status (=0.001) and maintenance regimens (=0.013) were independent prognostic factors for PFS. Both gefitinib and pemetrexed were well tolerated.

Conclusion: Gefitinib compared with pemetrexed as maintenance therapy had a significantly longer PFS and a similar OS with good tolerability in patients with advanced lung adenocarcinoma. Moreover, for EGFR mutation-positive patients, gefitinib maintenance had a significantly longer PFS; however, pemetrexed maintenance was considered more effective for EGFR wild-type patients.

Citing Articles

Noncoding SNP at rs1663689 represses ADGRG6 via interchromosomal interaction and reduces lung cancer progression.

Lei X, Tian X, Wang H, Xu X, Li G, Liu W EMBO Rep. 2023; 24(7):e56212.

PMID: 37154297 PMC: 10328068. DOI: 10.15252/embr.202256212.

The functional roles of the circRNA/Wnt axis in cancer.

Xue C, Li G, Zheng Q, Gu X, Bao Z, Lu J Mol Cancer. 2022; 21(1):108.

PMID: 35513849 PMC: 9074313. DOI: 10.1186/s12943-022-01582-0.

Efficacy and Safety of Gefitinib Plus Pemetrexed/Platinum in Advanced EGFR-Mutated Lung Adenocarcinoma Patients: A Real-World Observational Study.

Wang R, Wu Q Onco Targets Ther. 2022; 15:31-39.

PMID: 35046665 PMC: 8763260. DOI: 10.2147/OTT.S332998.

A meta-analysis of the safety and effectiveness of pemetrexed compared with gefitinib for pre-treated advanced or metastatic NSCLC.

Lu X, Li S, Chen W, Zheng D, Li Y, Li F Medicine (Baltimore). 2020; 99(29):e21170.

PMID: 32702875 PMC: 7373595. DOI: 10.1097/MD.0000000000021170.

Impact of Weight Loss at Presentation on Survival in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) Sensitive Mutant Advanced Non-small Cell Lung Cancer (NSCLC) Treated with First-line EGFR-TKI.

Lin L, Zhao J, Hu J, Huang F, Han J, He Y J Cancer. 2018; 9(3):528-534.

PMID: 29483958 PMC: 5820920. DOI: 10.7150/jca.22378.

References

Stinchcombe T, Socinski M . Maintenance therapy in advanced non-small cell lung cancer: current status and future implications. J Thorac Oncol. 2010; 6(1):174-82. DOI: 10.1097/JTO.0b013e318200f9c5. View

Goldstraw P, Crowley J, Chansky K, Giroux D, Groome P, Rami-Porta R . The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007; 2(8):706-14. DOI: 10.1097/JTO.0b013e31812f3c1a. View

Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol J, Bidoli P . PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013; 31(23):2895-902. DOI: 10.1200/JCO.2012.47.1102. View

Tan P, Lopes G, Acharyya S, Bilger M, Haaland B . Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: results by performance status, EGFR.... Eur J Cancer. 2015; 51(16):2330-44. DOI: 10.1016/j.ejca.2015.07.007. View

Zhou Q, Cheng Y, Yang J, Zhao M, Zhang L, Zhang X . Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial. Ann Oncol. 2014; 25(12):2385-2391. DOI: 10.1093/annonc/mdu463. View

Lu S, Yu Y, Chen Z, Ye X, Li Z, Niu X . Maintenance Therapy Improves Survival Outcomes in Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of 14 Studies. Lung. 2015; 193(5):805-14. DOI: 10.1007/s00408-015-9758-y. View

Johkoh T, Sakai F, Kusumoto M, Arakawa H, Harada R, Ueda M . Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib--a cohort study. Clin Lung Cancer. 2014; 15(6):448-54. DOI: 10.1016/j.cllc.2014.06.003. View

Zhang L, Ma S, Song X, Han B, Cheng Y, Huang C . Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol. 2012; 13(5):466-75. DOI: 10.1016/S1470-2045(12)70117-1. View

Pujol J, Paz-Ares L, de Marinis F, Dediu M, Thomas M, Bidoli P . Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced.... Clin Lung Cancer. 2014; 15(6):418-25. DOI: 10.1016/j.cllc.2014.06.007. View

10.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

11.

Zhou F, Jiang T, Ma W, Gao G, Chen X, Zhou C . The impact of clinical characteristics on outcomes from maintenance therapy in non-small cell lung cancer: A systematic review with meta-analysis. Lung Cancer. 2015; 89(2):203-11. DOI: 10.1016/j.lungcan.2015.06.005. View

12.

Tassinari D, Scarpi E, Sartori S, Tamburini E, Santelmo C, Tombesi P . Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials. Chest. 2009; 135(6):1596-1609. DOI: 10.1378/chest.08-1503. View

13.

Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View

14.

Mountain C . Revisions in the International System for Staging Lung Cancer. Chest. 1997; 111(6):1710-7. DOI: 10.1378/chest.111.6.1710. View

15.

Zhang C, Huang C, Wang J, Wang X, Li K . Maintenance or Consolidation Therapy for Non--Small-Cell Lung Cancer: A Meta-Analysis Involving 5841 Subjects. Clin Lung Cancer. 2015; 16(5):e15-23. DOI: 10.1016/j.cllc.2015.01.002. View

16.

Kim Y, Cho E, Woo H, Hong J, Ahn H, Park I . Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer. Cancer Res Treat. 2015; 48(1):80-7. PMC: 4720098. DOI: 10.4143/crt.2014.307. View

17.

Xue C, Hu Z, Jiang W, Zhao Y, Xu F, Huang Y . National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China. Lung Cancer. 2012; 77(2):371-5. DOI: 10.1016/j.lungcan.2012.04.014. View

18.

Sun J, Lee K, Kim S, Lee D, Min Y, Yun H . Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial. Cancer. 2012; 118(24):6234-42. DOI: 10.1002/cncr.27630. View

19.

Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr K, Peters S . Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25 Suppl 3:iii27-39. DOI: 10.1093/annonc/mdu199. View

20.

Kuo L, Lin P, Wang K, Yuan M, Chang S . Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review. Med Oncol. 2010; 28(1):79-82. DOI: 10.1007/s12032-010-9424-4. View